- Home
- MATH vs BDTX Comparison
MATH vs BDTX Comparison
Compare MATH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MATH | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MATH | BDTX |
|---|---|---|
| Price | $2.32 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 82.7K | ★ 1.6M |
| Earning Date | 12-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | 0.38 |
| Revenue | $44,567,257.00 | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $5.78 | $6.72 |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $0.99 | $1.20 |
| 52 Week High | $4.17 | $4.94 |
Technical Indicators
Market Signals| Indicator | MATH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 28.57 |
| Support Level | $2.84 | $2.61 |
| Resistance Level | $3.04 | $2.72 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 8.54 | 20.18 |
Price Performance
Historical ComparisonAbout MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.